WCLC 2025 - Posters & ePosters-P3.12.40 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION

P3.12.40 Safety and Patient-Reported Outcomes With Tepotinib in Patients With METex14 Skipping NSCLC: =3-Years Follow-Up of VISION

Asset Subtitle

Enriqueta Felip

Meta Tag

Speaker Enriqueta Felip

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy